vs
Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $134.9M, roughly 1.4× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 0.9%, a 81.6% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 23.7%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 29.5%).
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
CTRE vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $134.9M | $185.2M |
| Net Profit | $111.3M | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | — | 8.6% |
| Net Margin | 82.5% | 0.9% |
| Revenue YoY | 55.1% | 23.7% |
| Net Profit YoY | 113.5% | -88.5% |
| EPS (diluted) | $0.52 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.9M | $185.2M | ||
| Q3 25 | $132.4M | $169.1M | ||
| Q2 25 | $112.5M | $154.7M | ||
| Q1 25 | $96.6M | $125.2M | ||
| Q4 24 | $86.9M | $149.7M | ||
| Q3 24 | $77.4M | $141.5M | ||
| Q2 24 | $68.9M | $126.7M | ||
| Q1 24 | $63.1M | $110.4M |
| Q4 25 | $111.3M | $1.7M | ||
| Q3 25 | $74.9M | $17.3M | ||
| Q2 25 | $68.5M | $-24.4M | ||
| Q1 25 | $65.8M | $-21.7M | ||
| Q4 24 | $52.1M | $14.7M | ||
| Q3 24 | $33.4M | $-6.7M | ||
| Q2 24 | $10.8M | $-15.7M | ||
| Q1 24 | $28.7M | $-48.4M |
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% | ||
| Q1 24 | — | 87.7% |
| Q4 25 | — | 8.6% | ||
| Q3 25 | 58.1% | 20.3% | ||
| Q2 25 | 61.3% | -6.1% | ||
| Q1 25 | — | -6.3% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | 43.0% | 15.3% | ||
| Q2 24 | 15.1% | 11.8% | ||
| Q1 24 | — | -25.1% |
| Q4 25 | 82.5% | 0.9% | ||
| Q3 25 | 56.6% | 10.2% | ||
| Q2 25 | 60.9% | -15.8% | ||
| Q1 25 | 68.1% | -17.3% | ||
| Q4 24 | 60.0% | 9.8% | ||
| Q3 24 | 43.2% | -4.8% | ||
| Q2 24 | 15.6% | -12.4% | ||
| Q1 24 | 45.6% | -43.9% |
| Q4 25 | $0.52 | $0.00 | ||
| Q3 25 | $0.35 | $0.06 | ||
| Q2 25 | $0.35 | $-0.08 | ||
| Q1 25 | $0.35 | $-0.07 | ||
| Q4 24 | $0.30 | $0.05 | ||
| Q3 24 | $0.21 | $-0.02 | ||
| Q2 24 | $0.07 | $-0.05 | ||
| Q1 24 | $0.22 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.0M | $293.5M |
| Total DebtLower is stronger | $894.2M | $392.7M |
| Stockholders' EquityBook value | $4.0B | $274.2M |
| Total Assets | $5.1B | $949.9M |
| Debt / EquityLower = less leverage | 0.22× | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.0M | $293.5M | ||
| Q3 25 | $712.5M | $263.8M | ||
| Q2 25 | $306.1M | $231.0M | ||
| Q1 25 | $26.5M | $250.6M | ||
| Q4 24 | $213.8M | $249.9M | ||
| Q3 24 | $377.1M | $249.8M | ||
| Q2 24 | $495.1M | $260.1M | ||
| Q1 24 | $451.2M | $239.6M |
| Q4 25 | $894.2M | $392.7M | ||
| Q3 25 | $893.8M | $392.0M | ||
| Q2 25 | $1.2B | $391.3M | ||
| Q1 25 | $822.1M | $390.7M | ||
| Q4 24 | $396.9M | $390.1M | ||
| Q3 24 | $396.7M | $389.5M | ||
| Q2 24 | $671.1M | $388.9M | ||
| Q1 24 | $595.9M | $388.4M |
| Q4 25 | $4.0B | $274.2M | ||
| Q3 25 | $4.0B | $230.4M | ||
| Q2 25 | $3.3B | $204.3M | ||
| Q1 25 | $2.9B | $193.6M | ||
| Q4 24 | $2.9B | $194.0M | ||
| Q3 24 | $2.4B | $178.8M | ||
| Q2 24 | $1.9B | $132.5M | ||
| Q1 24 | $1.7B | $130.7M |
| Q4 25 | $5.1B | $949.9M | ||
| Q3 25 | $5.1B | $868.8M | ||
| Q2 25 | $4.7B | $815.3M | ||
| Q1 25 | $3.9B | $789.8M | ||
| Q4 24 | $3.4B | $785.0M | ||
| Q3 24 | $2.9B | $786.6M | ||
| Q2 24 | $2.7B | $749.5M | ||
| Q1 24 | $2.3B | $721.8M |
| Q4 25 | 0.22× | 1.43× | ||
| Q3 25 | 0.22× | 1.70× | ||
| Q2 25 | 0.35× | 1.92× | ||
| Q1 25 | 0.28× | 2.02× | ||
| Q4 24 | 0.14× | 2.01× | ||
| Q3 24 | 0.16× | 2.18× | ||
| Q2 24 | 0.35× | 2.93× | ||
| Q1 24 | 0.36× | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $394.0M | $16.3M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 8.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 3.54× | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $394.0M | $16.3M | ||
| Q3 25 | $100.9M | $35.7M | ||
| Q2 25 | $100.8M | $-26.5M | ||
| Q1 25 | $71.4M | $7.8M | ||
| Q4 24 | $244.3M | $-3.9M | ||
| Q3 24 | $67.2M | $-23.0M | ||
| Q2 24 | $53.0M | $22.7M | ||
| Q1 24 | $48.8M | $-29.7M |
| Q4 25 | — | $16.0M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $-28.9M | ||
| Q1 25 | — | $7.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | — | $-23.3M | ||
| Q2 24 | — | $21.6M | ||
| Q1 24 | — | $-31.5M |
| Q4 25 | — | 8.6% | ||
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | -18.7% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | — | -16.5% | ||
| Q2 24 | — | 17.0% | ||
| Q1 24 | — | -28.5% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | 3.54× | 9.62× | ||
| Q3 25 | 1.35× | 2.06× | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 4.68× | -0.27× | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRE
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
